Sigma upgrades kilo capacity with second lab
manufacturing for active pharmaceutical ingredients (APIs) at its
Buchs production site in Switzerland.
The newly opened kilo lab is for the production of gram-to-several kilogram quantities of APIs and key intermediates for preclinical phase to Phase II clinical studies, and expands Sigma contract development and manufacturing services to the pharmaceutical industry.
The lab is based on simulated moving bed (SMB) separation technology and has been designed to address drawbacks of scale-up from benchtop to production that can lead to loss of time and money during the development of a new drug, according to the company.
Sigma says that the SMB technology overcome the problems associated with separation techniques, such as preparative-scale, high-performance liquid chromatography (HPLC).
The kilo lab complements Sigma's existing fully-segregated cGMP kilo lab facilities at Gillingham in Dorset, UK.
